Biomednewsbreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Two Years Of Clinical Milestones Across Oncology And Rare Disease Programs

(MENAFN- Investor Brand Network) Oncotelic Therapeutics (OTCQB: OTLC) , a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, announced a summary of major accomplishments achieved over the past two years. The update highlights progress across multiple late-stage programs, including OT-101, now in Phase 3 for pancreatic cancer with additional applications in ARDS/COVID-19, and OXi4503, advancing from Phase 2 in AML/MDS toward pivotal Phase 3 design. Other assets include CA4P/Fosbretabulin, AL-101 for Parkinson's disease and sexual dysfunctions, AL-102 in discovery for Alzheimer's disease, pediatric rare disease programs with potential Priority Review Vouchers, and a nanomedicine pipeline advancing several 505(b)(2) drug candidates. CEO Dr. Vuong Trieu said the progress strengthens the Company's position as a late-stage biotech with broad value creation potential across multi-billion-dollar markets with high unmet need.

To view the full press release, visit

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company's mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the Company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu's leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic's strategic position in oncology and rare disease therapeutics.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

MENAFN12092025000224011066ID1110054546